![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
A 75-y-old Chinese female patient diagnosed with lung adenocarcinoma with brain metastasis suffered severe nausea and vomiting, and these symptoms were contraindications for CyberKnife treatment. Neither mannitol, nor dexamethasone, relieved the symptoms. However, after the patient received a single dose of bevacizumab (200 mg, 2.9 mg/kg), the patient's symptoms were significantly relieved. The patient subsequently completed a successful CyberKnife treatment. In addition, the patient received an oral treatment of gefitinib. At 15 months post treatment, the patient's brain tumor was controlled. Thus, administration of bevacizumab at a low dose (2.9 mg/kg) may significantly alleviate peri-tumoral brain edema and its symptoms, thereby facilitating radiosurgery treatment.
Abbreviations
| EI | = | Edema index |
| IMRT | = | Intensity-modulated radiation therapy |
| MRI | = | Magnetic resonance imaging |
| NSCLC | = | Non-small cell lung cancer |
| PTBE | = | Peritumoral brain edema |
| VEGF-A | = | Vascular endothelial growth factor A |
Conflicts of interest
The authors have no potential conflicts of interest.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.